If the end goal in healthtech is improve care for patients, then Regenity CEO Shawn McCarthy is well on his way. After all, he vows that “in the end, we want to make a material difference in the lives of patients,” he said on a podcast earlier this year. “And we do that quite often.”
The Syracuse University graduate has been making his name in the healthcare technology field for almost 35 years now, the last 5 of which he’s spent running Regenity. “The evolution of the business, what’s really exciting, is that we continue to innovate in a way that allows us to be changing standards of care to create solutions that are really, truly, definitive, and that we can make the first treatment last.”
Regenity is a trailblazer in hard and soft tissue regeneration, and is co-headquartered in Paramus, NJ and Groningen, in the Netherlands, with a three-pronged goal: Reinvent. Re-Energize. Regenerate. Which, under McCarthy’s leadership, the business has been doing apace in the last year. Most notably, the company introduced the proprietary RejuvaKnee, “a revolutionary meniscus implant device that facilitates the regeneration of the native meniscal tissue as an alternative to traditional approaches that cut or replace it.”
All of that, medspeak included, is to say that McCarthy has a steady hand on the wheel, and is keeping his company focused on making that difference for patients “by transforming bioresorbable materials into life-changing solutions,” of which RejuvaKnee certainly qualifies. The company has similar aims across many different applications, from dental care to ENT surgery, nerve repair, and even technology platforms that support the development of bioresorbable and biocompatible devices.
If “Regenity” was a verb, that’s more or less what it would signify: regeneration, based on health tech, that works on its own. And McCarthy is continuing to push that mission forward.
